Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Select Advanced Solid Tumors 1Recurrence 1Pregnancy Related 1Neuroblastoma 1Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Endometrial Neoplasms 1

Interventions

pembrolizumab 91Blood Specimen Collection 43Cyclophosphamide 37Nivolumab 36Bevacizumab 36Standard of Care 32Carboplatin 31Surveys and Questionnaires 29Paclitaxel 27atezolizumab 25Exercise 25Pemetrexed 24Gemcitabine 24Cisplatin 23Fluorouracil 22Radiotherapy 20Leucovorin 20Dexamethasone 20Oxaliplatin 19Docetaxel 19Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Drug Therapy 15Doxorubicin 15Biopsy 15130-nm albumin-bound paclitaxel 15Prednisone 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Antibodies, Monoclonal × 1 year × Clear all
NCT06840119 2026-01-28

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Immunocore Ltd

Phase 1/2 Recruiting
600 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡